- Home
- ATAI vs PVLA Comparison
ATAI vs PVLA Comparison
Compare ATAI & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- PVLA
- Stock Information
- Founded
- ATAI 2018
- PVLA 2015
- Country
- ATAI Germany
- PVLA United States
- Employees
- ATAI N/A
- PVLA N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- PVLA Health Care
- Exchange
- ATAI Nasdaq
- PVLA Nasdaq
- Market Cap
- ATAI 291.5M
- PVLA 308.2M
- IPO Year
- ATAI 2021
- PVLA N/A
- Fundamental
- Price
- ATAI $1.24
- PVLA $23.59
- Analyst Decision
- ATAI Strong Buy
- PVLA Strong Buy
- Analyst Count
- ATAI 4
- PVLA 6
- Target Price
- ATAI $9.00
- PVLA $43.50
- AVG Volume (30 Days)
- ATAI 1.7M
- PVLA 93.0K
- Earning Date
- ATAI 03-17-2025
- PVLA 05-15-2025
- Dividend Yield
- ATAI N/A
- PVLA N/A
- EPS Growth
- ATAI N/A
- PVLA N/A
- EPS
- ATAI N/A
- PVLA N/A
- Revenue
- ATAI $308,000.00
- PVLA N/A
- Revenue This Year
- ATAI N/A
- PVLA N/A
- Revenue Next Year
- ATAI $20.00
- PVLA N/A
- P/E Ratio
- ATAI N/A
- PVLA N/A
- Revenue Growth
- ATAI N/A
- PVLA N/A
- 52 Week Low
- ATAI $1.03
- PVLA $6.20
- 52 Week High
- ATAI $2.85
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- ATAI 36.74
- PVLA N/A
- Support Level
- ATAI $1.42
- PVLA N/A
- Resistance Level
- ATAI $1.58
- PVLA N/A
- Average True Range (ATR)
- ATAI 0.12
- PVLA 0.00
- MACD
- ATAI -0.00
- PVLA 0.00
- Stochastic Oscillator
- ATAI 4.55
- PVLA 0.00
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.